COMMUNIQUÉS West-GlobeNewswire

Calidi Biotherapeutics Announces Pricing of $3.9 Million Registered Direct Offering and Concurrent Private Placement
28/03/2025
SAN DIEGO, March 28, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of targeted [...]
Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates
28/03/2025
UNLOXCYT™ (cosibelimab-ipdl) approved by U.S. FDA as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma WALTHAM, Mass., March 28, 2025 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“ [...]
Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data
28/03/2025
Silexion’s new expanded dual-route strategy will integrate intratumoral and systemic administration to target both primary tumors and metastases, supported by strong preclinical data from SIL204 and previous promising [...]
SS Innovations Continues its International Growth, Receiving Medical Device Regulatory Approvals for the SSi Mantra 3 Surgical Robotic System in both the Philippines and Ukraine
28/03/2025
FORT LAUDERDALE, Fla., March 28, 2025 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (OTC: SSII) (“SS Innovations” or the “Company”), a developer of innovative surgical robotic technologies dedicated to making [...]
Vivos Therapeutics Schedules Release of Full Year 2024 Financial Results and Conference Call
28/03/2025
Call Scheduled for Monday, March 31, 2025 at 5:00 pm ET LITTLETON, Colo., March 28, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS) , a leading medical device and technology [...]
Gain Therapeutics Announces Poster Presentation at AD/PD 2025
28/03/2025
BETHESDA, Md., March 28, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of [...]
Ocean Biomedical Announces Grant on Patent Right for Bispecific Antibodies Targeting CHI3L1 and PD1 for Enhanced Tumor Cell Cytotoxicity in China
28/03/2025
PROVIDENCE, R.I., March 28, 2025 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharmaceutical company dedicated to advancing innovative treatments for cancer, infectious diseases, and fibrosis, today [...]
Intelligent Bio Solutions to Highlight Proprietary Drug Testing Technology at 2025 NDASA Conference and Trade Show
28/03/2025
NEW YORK, March 28, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today [...]
Aptose Reports Year End 2024 Results and Corporate Highlights
28/03/2025
Tuspetinib Triple Drug Frontline Therapy Advancing in TUSCANY Clinical Trial Results to Date Highlight TUS Potential as an Ideal Third Drug to Include in AML Triplet Therapy Aptose Signs Debt Conversion Agreement with [...]
Tr1X Announces Succession Plan: Appoints David de Vries CEO, Effective June 1; Bill Lis to Serve as Executive Chairman
28/03/2025
SAN DIEGO, March 28, 2025 (GLOBE NEWSWIRE) -- Tr1X, Inc. (pronounced “Trix”), a clinical-stage biopharmaceutical company developing first-in-class allogeneic engineered Treg and CAR-Treg cell therapies with the [...]
Daxor Expands Blood Volume Analysis Technology Across Midwest, Wisconsin, and New Jersey Healthcare Networks
28/03/2025
Regional Medical Leaders Embrace Daxor’s ezBVA Lab Service Oak Ridge, TN, March 28, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), Daxor, the global leader in blood volume measurement technology, today [...]
Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity
28/03/2025
CB1 inverse agonism is a clinically validated mechanism to induce weight loss CRB-913 is markedly more peripherally restricted compared to monlunabant and rimonabant SAD/MAD Phase 1 trial scheduled for completion Q3 [...]
Catheter Precision, Inc. Announces Fourth Quarter and Full Year 2024 Update and Financial Results
28/03/2025
FORT MILL, S.C., March 28, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced its financial [...]
Lexicon Pharmaceuticals Announces Exclusive License Agreement with Novo Nordisk for LX9851
28/03/2025
Lexicon eligible to receive up to $1 billion in upfront and development, regulatory and sales milestone payments, including $75 million in upfront and near-term milestone payments THE WOODLANDS, Texas, March 28, 2025 ( [...]
LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
28/03/2025
Focused on the evaluation of strategic alternatives Adopted a restructuring plan to extend capital resources, incurring a reduction in workforce of 30% to support the evaluation of strategic options and the Phase 1 [...]
Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress
28/03/2025
- Preliminary efficacy data from Phase 1/2 dose expansion cohort show durable responses and tumor shrinkage in a PD-(L)1 resistant “hot” tumor patient population - - Solnerstotug continues to demonstrate a well- [...]
Humacyte Announces Fourth Quarter and Year End 2024 Financial Results and Provides Business Update
28/03/2025
- Received U.S. Food and Drug Administration (FDA) approval of Symvess™ (acellular tissue engineered vessel-tyod) for the treatment of extremity vascular trauma - - Commenced market launch and first commercial sales of [...]
TREMFYA® (guselkumab) receives positive CHMP opinion for treatment of patients with moderately to severely active Crohn’s Disease
28/03/2025
Recommendation based on the findings from the Phase 3 studies (GALAXI programme and GRAVITI) in Crohn’s disease 1 , 2 , 3 Beerse, Belgium (28 March 2025) – Johnson & Johnson today announced that the Committee for [...]
FDA Issues Complete Response Letter for Etripamil for PSVT
28/03/2025
CRL focused on CMC; no clinical issues relating to etripamil raised $69.7M in cash, cash equivalents and short-term investments as of December 31, 2024 MONTREAL and CHARLOTTE, N.C., March 28, 2025 (GLOBE NEWSWIRE) -- [...]

Pages